Cost of benign versus oncologic colon resection among fee-for-service Medicare enrollees

Byron D. Hughes, Kevin J. Hancock, Yong Shan, Ravi A. Thakker, Safa Maharsi, Douglas Tyler, Hemalkumar Mehta, Anthony J. Senagore

Research output: Contribution to journalArticle

Abstract

Background and Objectives: Reimbursement for colonic pathology by the Centers for Medicare and Medicaid Services (CMS) are grouped in the Medicare Severity-Diagnosis Related Groups (MS-DRG). With limited available data, we sought to compare the relative impact of malignant vs benign colonic pathology on reimbursement under the MS-DRG system. Methods: We used 5% national Medicare data from 2011 to 2014. Patients were classified as having benign disease or malignancy. Descriptive statistics and multivariate regression analysis were used to evaluate the surgical approach and health resource utilization. Results: Of 10 928 patients, most were Non-Hispanic White women. The majority underwent open colectomy in both cohorts (P <.001). Colectomy for benign disease was associated with higher total charges (P <.001) and a longer length of stay (P =.0002). Despite higher charges, payments were not significantly different between the cohorts (P =.434). Both inpatient mortality and discharge to a rehab facility were higher in the oncologic group (P <.001). Conclusion: Payment methodology for colectomy under the CMS MS-DRG system does not appear to accurately reflect the episode cost of care. The data suggest that inpatient costs are not fully compensated. A transition to value-based payments with expanded episode duration will require a better understanding of unique costs before adoption.

Original languageEnglish (US)
Pages (from-to)280-286
Number of pages7
JournalJournal of Surgical Oncology
Volume120
Issue number2
DOIs
StatePublished - Aug 1 2019

Fingerprint

Fee-for-Service Plans
Medicare
Colectomy
Diagnosis-Related Groups
Colon
Costs and Cost Analysis
Centers for Medicare and Medicaid Services (U.S.)
Inpatients
Episode of Care
Pathology
Health Resources
Length of Stay
Multivariate Analysis
Regression Analysis
Mortality
Neoplasms

Keywords

  • colectomy
  • DRG migration
  • Medicare
  • value-based care

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Hughes, B. D., Hancock, K. J., Shan, Y., Thakker, R. A., Maharsi, S., Tyler, D., ... Senagore, A. J. (2019). Cost of benign versus oncologic colon resection among fee-for-service Medicare enrollees. Journal of Surgical Oncology, 120(2), 280-286. https://doi.org/10.1002/jso.25511

Cost of benign versus oncologic colon resection among fee-for-service Medicare enrollees. / Hughes, Byron D.; Hancock, Kevin J.; Shan, Yong; Thakker, Ravi A.; Maharsi, Safa; Tyler, Douglas; Mehta, Hemalkumar; Senagore, Anthony J.

In: Journal of Surgical Oncology, Vol. 120, No. 2, 01.08.2019, p. 280-286.

Research output: Contribution to journalArticle

Hughes, BD, Hancock, KJ, Shan, Y, Thakker, RA, Maharsi, S, Tyler, D, Mehta, H & Senagore, AJ 2019, 'Cost of benign versus oncologic colon resection among fee-for-service Medicare enrollees', Journal of Surgical Oncology, vol. 120, no. 2, pp. 280-286. https://doi.org/10.1002/jso.25511
Hughes, Byron D. ; Hancock, Kevin J. ; Shan, Yong ; Thakker, Ravi A. ; Maharsi, Safa ; Tyler, Douglas ; Mehta, Hemalkumar ; Senagore, Anthony J. / Cost of benign versus oncologic colon resection among fee-for-service Medicare enrollees. In: Journal of Surgical Oncology. 2019 ; Vol. 120, No. 2. pp. 280-286.
@article{5c6606d1ca884b7cbd14084cc208566d,
title = "Cost of benign versus oncologic colon resection among fee-for-service Medicare enrollees",
abstract = "Background and Objectives: Reimbursement for colonic pathology by the Centers for Medicare and Medicaid Services (CMS) are grouped in the Medicare Severity-Diagnosis Related Groups (MS-DRG). With limited available data, we sought to compare the relative impact of malignant vs benign colonic pathology on reimbursement under the MS-DRG system. Methods: We used 5{\%} national Medicare data from 2011 to 2014. Patients were classified as having benign disease or malignancy. Descriptive statistics and multivariate regression analysis were used to evaluate the surgical approach and health resource utilization. Results: Of 10 928 patients, most were Non-Hispanic White women. The majority underwent open colectomy in both cohorts (P <.001). Colectomy for benign disease was associated with higher total charges (P <.001) and a longer length of stay (P =.0002). Despite higher charges, payments were not significantly different between the cohorts (P =.434). Both inpatient mortality and discharge to a rehab facility were higher in the oncologic group (P <.001). Conclusion: Payment methodology for colectomy under the CMS MS-DRG system does not appear to accurately reflect the episode cost of care. The data suggest that inpatient costs are not fully compensated. A transition to value-based payments with expanded episode duration will require a better understanding of unique costs before adoption.",
keywords = "colectomy, DRG migration, Medicare, value-based care",
author = "Hughes, {Byron D.} and Hancock, {Kevin J.} and Yong Shan and Thakker, {Ravi A.} and Safa Maharsi and Douglas Tyler and Hemalkumar Mehta and Senagore, {Anthony J.}",
year = "2019",
month = "8",
day = "1",
doi = "10.1002/jso.25511",
language = "English (US)",
volume = "120",
pages = "280--286",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Cost of benign versus oncologic colon resection among fee-for-service Medicare enrollees

AU - Hughes, Byron D.

AU - Hancock, Kevin J.

AU - Shan, Yong

AU - Thakker, Ravi A.

AU - Maharsi, Safa

AU - Tyler, Douglas

AU - Mehta, Hemalkumar

AU - Senagore, Anthony J.

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Background and Objectives: Reimbursement for colonic pathology by the Centers for Medicare and Medicaid Services (CMS) are grouped in the Medicare Severity-Diagnosis Related Groups (MS-DRG). With limited available data, we sought to compare the relative impact of malignant vs benign colonic pathology on reimbursement under the MS-DRG system. Methods: We used 5% national Medicare data from 2011 to 2014. Patients were classified as having benign disease or malignancy. Descriptive statistics and multivariate regression analysis were used to evaluate the surgical approach and health resource utilization. Results: Of 10 928 patients, most were Non-Hispanic White women. The majority underwent open colectomy in both cohorts (P <.001). Colectomy for benign disease was associated with higher total charges (P <.001) and a longer length of stay (P =.0002). Despite higher charges, payments were not significantly different between the cohorts (P =.434). Both inpatient mortality and discharge to a rehab facility were higher in the oncologic group (P <.001). Conclusion: Payment methodology for colectomy under the CMS MS-DRG system does not appear to accurately reflect the episode cost of care. The data suggest that inpatient costs are not fully compensated. A transition to value-based payments with expanded episode duration will require a better understanding of unique costs before adoption.

AB - Background and Objectives: Reimbursement for colonic pathology by the Centers for Medicare and Medicaid Services (CMS) are grouped in the Medicare Severity-Diagnosis Related Groups (MS-DRG). With limited available data, we sought to compare the relative impact of malignant vs benign colonic pathology on reimbursement under the MS-DRG system. Methods: We used 5% national Medicare data from 2011 to 2014. Patients were classified as having benign disease or malignancy. Descriptive statistics and multivariate regression analysis were used to evaluate the surgical approach and health resource utilization. Results: Of 10 928 patients, most were Non-Hispanic White women. The majority underwent open colectomy in both cohorts (P <.001). Colectomy for benign disease was associated with higher total charges (P <.001) and a longer length of stay (P =.0002). Despite higher charges, payments were not significantly different between the cohorts (P =.434). Both inpatient mortality and discharge to a rehab facility were higher in the oncologic group (P <.001). Conclusion: Payment methodology for colectomy under the CMS MS-DRG system does not appear to accurately reflect the episode cost of care. The data suggest that inpatient costs are not fully compensated. A transition to value-based payments with expanded episode duration will require a better understanding of unique costs before adoption.

KW - colectomy

KW - DRG migration

KW - Medicare

KW - value-based care

UR - http://www.scopus.com/inward/record.url?scp=85068960071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068960071&partnerID=8YFLogxK

U2 - 10.1002/jso.25511

DO - 10.1002/jso.25511

M3 - Article

VL - 120

SP - 280

EP - 286

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 2

ER -